4th Quarter - Report

SEQIRUS for SEQIRUS

Period 4th Quarter 2022 Filed Jan 20, 2023 Signed by James Sherner

Official filing
Firm
SEQIRUS
Client
SEQIRUS
Income
—
Expenses
$230,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

FY2023 Appropriations, FY2023 President's Budget proposals, supplemental appropriations, seasonal and pandemic influenza preparedness, H.R. 9476 Protecting America from Seasonal and Pandemic Influenza Act of 2022

Foreign entity interest: CSL Limited, identified on Registration (LD-1), is the parent company of Seqirus and benefits from the financial success thereof.

LobbyistCovered position, as disclosed
CHRISTINE FARQUHARSON —

Contacted: HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Natl Security Council (NSC); SENATE

Bills named: H.R. 9476 (117th)

Health Issues HCR

H.R. 9476 Protecting America from Seasonal and Pandemic Influenza Act of 2022; issues related to pandemic preparedness and seasonal and pandemic influenza preparedness.

Foreign entity interest: CSL Limited, identified on Registration (LD-1), is the parent company of Seqirus and benefits from the financial success thereof.

LobbyistCovered position, as disclosed
CHRISTINE FARQUHARSON —

Contacted: Health & Human Services, Dept of (HHS); SENATE; Natl Security Council (NSC); Defense, Dept of (DOD); HOUSE OF REPRESENTATIVES; Office of Science & Technology Policy (OSTP)

Bills named: H.R. 9476 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.